However, the renal beneficial effect of SGLT2-i has been definitely reported in recent cardiovascular outcome clinical trials and further confirmed in CREDENCE, DAPA-CKD, EMPA-KIDNEY, which investigated renal outcomes as primary endpoints also in non-diabetic patients with chronic kidney disease (48). Here, SLC5A2 is linked to chronic kidney disease.